Clinical-stage biotechnology company developing cell and gene therapies for cancer and genetic diseases.
Poseida Therapeutics, Inc., a dynamic clinical-stage biopharmaceutical company headquartered in San Diego, California, is dedicated to advancing innovative therapies for patients facing significant unmet medical needs. At the forefront of its pipeline is P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) therapy currently undergoing Phase I trials for metastatic castrate-resistant prostate cancer (mCRPC). The company also focuses on P-BCMA-ALLO1, in Phase I trials for relapsed/refractory multiple myeloma, and P-MUC1C-ALLO1, targeting various solid tumors such as breast and ovarian cancers.
Founded in 2014, Poseida Therapeutics leverages its expertise in genetic medicine to develop a diverse portfolio that includes P-CD19CD20-ALLO1 for B cell malignancies and autoimmune diseases, and P-BCMACD19-ALLO1, an allogeneic CAR-T product in preclinical stages for multiple myeloma. Additionally, the company is advancing P-PSMA-ALLO1, an allogeneic CAR-T therapy for mCRPC. Poseida Therapeutics also pioneers liver-directed gene therapies with clinical stage candidates P-OTC-101 and P-FVIII-101, alongside innovative allogeneic dual CAR approaches.
In strategic collaboration with Takeda Pharmaceutical Company Limited, Poseida Therapeutics strengthens its research and development capabilities to accelerate the delivery of transformative therapies to patients worldwide. This partnership underscores Poseida's commitment to harnessing cutting-edge science and technology to address complex medical challenges effectively.
Poseida Therapeutics continues to expand its impact in the biopharmaceutical industry through rigorous research, clinical development, and strategic partnerships. With a focus on advancing precision medicine and enhancing therapeutic outcomes, the company remains dedicated to driving innovation and improving the lives of patients with serious diseases.